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Poster Session II S361who received Palonosetron have not vomited through out the chemo
while 33% of Ondansetron group.
Conclusion:Even though Palonosetron is manufactured for oncol-
ogy patients, it is used for haematology patients. In our study Pal-
onosetron was compared to Ondansetron. According to our study
Palonosetron made a significant difference in preventing and re-
ducing the CINV. Unfortunately the data was collected retrospec-
tively for the Ondansetron group. Because of low number the
outcome data could not be transferable to the whole patient
group.580
RETROSPECTIVE STUDY TO DEFINE THE ULTIMATE TIMING FOR START-
ING STEM CELL COLLECTION IN THE AUTOLOGOUS SETTING AND TO
COMPARE ENGRAFTMENT DATA OF PATIENTS WHO ACHIEVE TARGET
DOSE IN GREATER THAN 4 VERSUS LESS THAN 4 COLLECTIONS
Smith, V.R., Tran, H.T., Dinh, Y.T., Guillermo-Pacheco, M.,
Rondon, G., Hosing, C.M.University of TexasMDAnderson Cancer Cen-
ter, Houston, TX
Peripheral blood stem cell collection after high dose chemother-
apy for autologous transplantation has been done routinely in
many institutions over the years; however, the criteria for starting
harvest are not standardized. Most institutions agree that circulat-
ing peripheral blood CD34+ cells is the strongest indicator for
planning Apheresis, but the timing of Apheresis collection remains
controversial. Optimization of PBSC collection for autologous
stem cell transplant is necessary for good standard of care and
cost-effectiveness. Most studies have concentrated on identifying
peripheral blood CD34+ thresholds that would result in good cells
yields in fewer apheresis days. Based on these results the apheresis
timing proposed are 5-30 circulating peripheral blood CD34+
cells.
The emergence of new mobilization strategies and rising health-
care costs has brought about a practice change. This tertiary cancer
center did a retrospective study to 1.) determine the optimal timing
for starting PBPC collections by evaluating if patients are more
likely to reach a target number of . / 5 5x106 CD34+ cells if
Apheresis is started when peripheral blood circulating CD34+ cells
are . / 5 15 cells per micro liter compared to starting Apheresis
when peripheral blood circulating CD34+ cells are less than 15 cells
per micro liter. 2.) To evaluate if engraftment is affected when tar-
get dose of . / 5 5x106 CD34+ cells are collected in \ / 5 4
Apheresis days compared to those patients who reach target dose
in . 4 Apheresis days.
In this IRB approved retrospective study we reviewed the chart
of all autologous stem cell transplant patients collected from Jan.
1, 2007-Dec. 31, 2007. We recorded the CD34+ count on the day
of collection and compared to see if there was a significant differ-
ence in the number of stem cells collected between the patients
who were collected with a circulating CD34+ cell count of less
than 15 per micro liter and those who collected with a CD34+
count of 15 or higher. We will correlate to find is there is a sig-
nificant difference in the number apheresis collections required
to collect the target dose, and if there is a difference in engraft-
ment when patients start the apheresis procedure with a circulat-
ing CD34+ cell count of 15 or higher versus those who start
collection when the circulating CD34+ cell count is less than
15. Analysis in ongoing, however preliminary data suggests
that there is not a significance difference in engraftment between
the two groups.581
CAREGIVERS HELPING IN RELIEVING PAIN – C.H.I.R.P. PROJECT
Edmisten, J.H., Prewitt, J., Martin, P.L., Little, K. Duke University
Hospital, Durham, NC
Children who undergo hematopoietic stem cell transplant
experience significant pain and discomfort related to the sideeffects of treatment. Standard methods of analgesia delivery, spe-
cifically patient controlled analgesia (PCA), are not appropriate
for young children as they do not have the cognitive ability to
connect their pain to alleviation with operating a PCA demand
button. Currently, Duke University Hospital policy does not al-
low caregivers to push the button due to concerns for patient
safety. Therefore, an adult caregiver in conjunction with the
nursing staff must assess the pain and intervene for the child.
This process is a setup for delay in pain treatment when nursing
staff are busy with other tasks and unable to push the PCA but-
ton when it is needed.
The CHIRP study will examine the feasibility and acceptance of
caregiver education in operating the PCA demand button in young
pediatric BMT patients who require pain control. This study will
evaluate the preparation of caregivers in assessing their child’s pain
and sedation levels while operating the PCA demand button. The
hypothesis is that inclusion of the family in the delivery of pain med-
ications will yield equivalent or better outcomes and facilitate transi-
tion to home.
Thirty children and families will be enrolled on this IRB approved
protocol. A dedicated study coordinator will provide comprehensive
education using different educational modalities. Materials are pro-
vided in written and video format to review. The focus of the educa-
tion is to provide the caregiver with basic knowledge of pain and
sedation assessment tools, basic knowledge of analgesia and side-ef-
fects, and when to recognize signs of distress. A post-test must be
passed for the caregiver to be an authorized operator of the PCA de-
mand button. Staff education is provided so that they can guide care-
givers with their assessment skills. When patients no longer need
analgesia the caregivers complete a survey to collect 1) their percep-
tions of safety, 2) their ability to determine when their child was in
pain, 3) their perceptions of effective and prompt intervention for
their child’s pain, and 4) overall satisfaction with pain control for
their child.582
THE TRANSITION FROM PARENT TO PATIENT DURING HEMATOPOIETIC
STEM CELL TRANSPLANT
Asmus, K.R. Froedtert Hospital and the Medical College of Wisconsin,
Milwaukee, WI
The experience of being a parent is completely transformed at
the moment of cancer diagnosis, and a greater disequilibrium oc-
curs in the patient’s life when treatment includes a hematopoietic
stem cell transplant (HSCT). A review of the literature sites that
role changes can be greatest for parents raising dependent children
as they quickly transition from parent to patient and attempt to
treat and eradicate their disease, while still trying to grasp and
hold on to the strings of ‘‘normalcy’’ as their child’s parent (Coyne,
2009; Billhult & Segesten, 2003). Today, nurses who care for
HSCT patients continue to observe the treatment to be both phys-
ically and emotionally high-risk due to increased vulnerability of
deadly infections and stress during the prolonged hospitalization.
Although there has been significant research on coping with cancer
treatment, there is only limited research on the specific experience
of parents with dependent children who are treated with a HSCT.
This phenomenon from parent to patient in the environment of
HSCT requires greater research in order to improve nursing care
that is sensitive to the emotional and social changes that result
due to intense treatment, lengthy hospitalization, and restricted in-
teraction with their dependent children in an effort to reduce expo-
sure to infection.
The purpose of this descriptive phenomenological research study
proposes to understand the experience of HSCT treatment and the
physical, emotional, and social changes that transpire for parents
with dependent children; battling to regain health, defeat cancer,
and maintain their role as their child’s parent. The Transition The-
ory (Meleis, 2010) is also incorporated to provide clarity to the phe-
nomenon. Overall, through the proposed research greater nursing
knowledge will be developed to help parents cope with the role
changes during HSCT.
